Why is Kilitch Drugs falling/rising?

As of 11-Sep, Kilitch Drugs (India) Ltd is experiencing a decline in its stock price, currently at 362.40, which reflects a decrease of 5.8 or 1.58%. The stock has underperformed its sector today by 2.05% and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has shown a slight decline of 0.01%, while it has significantly underperformed over the past month with a drop of 18.56%. Despite a healthy long-term growth in net sales and operating profit, the company faces challenges such as poor management efficiency indicated by a low return on equity of 7.27% and disappointing quarterly results, which have contributed to the recent price decline.
In the broader market context, the Sensex has increased by 1.03% over the past week, contrasting sharply with Kilitch Drugs' performance. This divergence highlights the stock's struggles relative to the overall market. The company's low debt-to-equity ratio and rising investor participation, with a notable increase in delivery volume, suggest some underlying strength; however, the lack of domestic mutual fund investment and the expensive valuation indicated by a price-to-book ratio of 3.1 may deter potential investors. Overall, while the stock has shown strong long-term growth, the recent performance metrics and management efficiency issues are likely driving the current downward trend.